Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Idiopathic Anaphylaxis
NCT00890162Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2009
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Idiopathic anaphylaxis (IA) comparing Omalizumab with Placebo (2 arms). Primary endpoint: Reduction in the Number and Timing of Anaphylactic Events at 6 months. Started Apr 2009; status: completed.
02
Drugs
omalizumab
03
Conditions
Idiopathic anaphylaxis (IA)
Beyond the preview
Go deeper on NCT00890162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00890162.